Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 860 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Survivor Guest Post: Living Breast-less June 18, 2019 Research Says That Your Birth Order Can Shape Your Personality April 4, 2019 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with... September 23, 2024 Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with... August 10, 2022 Load more HOT NEWS Opioid Use Drops Among Cancer Patients at End of Life ACHIEVE-2 Results of Oxaliplatin-Based Adjuvant Chemotherapy in Asian Patients with High-Risk... New on NCI’s Websites for November 2021 Metronomic Capecitabine as Adjuvant Therapy Provides Compelling Evidence In Locoregionally Advanced...
